

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF SUPERVISOR

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Zhang Jing (張敬) (“**Mr. Zhang**”) resigned as an employee representative supervisor of the Company with effect from September 18, 2025 due to personal career development reasons.

Mr. Zhang has confirmed that he has no disagreement with the Board and the supervisory committee of the Company (the “**Supervisory Committee**”) and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited.

The Company would like to take this opportunity to express its sincere gratitude to Mr. Zhang for his contribution to the Company during his tenure of service.

APPOINTMENT OF SUPERVISOR

The Board is pleased to announce that Dr. Wang Tao (王濤) (“**Dr. Wang**”), the executive director of the Research and Development Platform Department of the Company, was democratically elected as an employee representative supervisor of the second session of the Supervisory Committee on September 18, 2025. Pursuant to the Company’s articles of association, employee representative supervisors are elected democratically by the general meeting of employee representative, the general meeting of employees or in other ways, and are not subject to the approval of the Shareholders.

The term of office of Dr. Wang became effective from September 18, 2025 and will expire until the end of the second session of the Supervisory Committee. Dr. Wang will not receive any remuneration from the Company as an employee representative supervisor.

The biographical details of Dr. Wang are set out below:

Dr. Wang was born in 1978, aged 47. Dr. Wang has over 18 years of experience in the research and development of antibody and protein drugs within the pharmaceutical industry. Dr. Wang worked at Nanjingjinsirui Science & Technology Biology Corp. (南京金斯瑞生物科技股份有限公司), a company listed on the Stock Exchange (stock code: 1548), from September 2006 to March 2010, where he served as a supervisor of the antibody drug development department. From March 2010 to September 2011, he was a manager of the antibody drug development department at Beijing Anbaokang Biomedical Technology Co., Ltd. (北京安保康生物醫藥科技有限公司). In October 2011, he joined the Company and served as the deputy director of the antibody research and development department of the Company until August 2015. Dr. Wang served as the associate dean and the vice director of the pharmaceutical research institute at Changchun GeneScience Pharmaceutical Co., Ltd. (長春金賽藥業有限責任公司) from August 2015 to September 2023. From October 2023 to June 2024, he was the director of the pharmaceutical research institute at Northeast Pharmaceutical Group Co., Ltd. (東北製藥集團股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000597). From July 2024 to July 2025, Dr. Wang served as a senior executive director of the pharmaceutical research and development department at Xiamen Amoytop Biotech Co., Ltd. (廈門特寶生物工程股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688278). He rejoined the Company as the executive director of the Research and Development Platform Department in August 2025. Dr. Wang obtained his bachelor's degree in plant protection from Hunan Agricultural University (湖南農業大學) in the PRC in June 2002. He received his master's degree in plant pathology from South China Agricultural University (華南農業大學) in the PRC in June 2006. Dr. Wang obtained his doctor's degree in bio-medicine from Central South University (中南大學) in the PRC in June 2024. In addition, Dr. Wang received the Jilin Province Talent Development Fund Award (吉林省人才開發資金獎勵) in 2019.

Dr. Wang has confirmed that, save as disclosed above, as at the date of this announcement, he (i) did not hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) did not have other major appointments or professional qualifications; (iii) did not have any relationship with any director, supervisor, senior management, substantial shareholder or controlling shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; (iv) did not hold any other positions with the Company or other members of the Group; and (v) did not have any other interests in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, the Board is not aware of other information in respect of Dr. Wang's appointment as an employee representative supervisor of the Company that is required to be disclosed pursuant to the requirements set out in Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any matter that needs to be brought to the attention of the Shareholders.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.

Dr. Zhou Pengfei

Chairman of the Board, Executive Director and Chief Executive Officer

Wuhan, PRC, September 18, 2025

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.